Cannabis Science (CBIS) Collaborates with Patients Out of Time, Inc., a Global Patient Advocacy Organization Dedicated to Educating Health Professionals and the Public about Therapeutic Cannabis - App

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Cannabis Science (CBIS) Collaborates with Patients Out of Time, Inc., a Global Patient Advocacy Organization Dedicated to Educating Health Professionals and the Public about Therapeutic Cannabis


Cannabis Science (CBIS) Collaborates with Patients Out of Time, Inc., a Global Patient Advocacy Organization Dedicated to Educating Health Professionals and the Public about Therapeutic Cannabis

PR Newswire

COLORADO SPRINGS, Colo., Feb. 5, 2014 /PRNewswire/ -- (NASD OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, provides development consultation and financial support to Patients Out of Time, Inc., the premiere non-profit organization devoted to helping educate the public and healthcare professionals about the safety and effectiveness of medical cannabis. Cannabis Science is pleased to facilitate the critical work of this unique non-profit organization's ongoing conferences, events, workshops and global distribution of leading edge educational content and online resources.

CBIS's support includes supporting Patients Out of Time's marquee conference in Portland, Oregon in May 2014, entitled "The Eighth National Clinical Conference on Cannabis Therapeutics", and future conferences, helping to expand the organization's conferences from biennial to annual, for which participants or learners may earn ACCME (fully recognized continuing education) credits.

Patients Out of Time is a patient advocacy organization dedicated to educating health professionals and the public about therapeutic uses of cannabis. Incorporated in 1995, the organization is closely associated with leading research scientists on a global basis, medical and nursing professionals, and the four remaining patient participants in the federal government's Investigational New Drug (IND) program for cannabis.

"Attending Patients Out of Time's 2010 Conference led to my departure from the financial industry and my ongoing work in the medical cannabis industry.  I feel both lucky and blessed for that experience, as it taught me one of the most important lessons:  this industry is about patients and their health, not about getting high.  I like to say that it is not an accident that the first word in the organization's name is 'Patients'.   We look forward to the Portland conference in May, a conference that has become internationally renowned and a source of great pride for all involved," stated Robert Kane, Director and CFO of Cannabis Science.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.

Dr. Dorothy Bray, CEO & Director
dorothy.bray@cannabisscience.com
Tel: 1.888.777.0658
www.cannabisscience.com
info@cannabisscience.com

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824

SOURCE Cannabis Science, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here